Eli Lilly & Co. supports the idea of introducing lower-priced branded drug alternatives to existing high-priced, highly-rebated drugs so that manufacturers and payers can more gradually transition to a system that is less dependent on rebates.
The concept is being floated by pharmacy benefit manager (PBM) Express Scripts Holding Co. as a near-term solution to high prices
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?